Clinicalinfo Sitemap
Home page
Main navigation
Guidelines
- Lenacapavir
-
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
- What's New in the Guidelines
- Panel Roster
- Financial Disclosure
- Statin Therapy in People With HIV
- Baseline Evaluation
-
Introduction
- Table 1. Outline of the Guidelines Development Process
- Table 2. Rating Scheme for Recommendations
-
Laboratory Testing
- Tests for Initial Assessment and Follow-up
-
Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring
- Table 4. Recommendations on the Indications and Frequency of Viral Load and CD4 Count Monitoring
-
Drug-Resistance Testing
- Table 5. Recommendations for the Use of Drug-Resistance Assays
- Co-Receptor Tropism Assays
- HLA-B* 5701 Screening
- Treatment Goals
- Initiation of Antiretroviral Therapy
- Antiretroviral Therapy to Prevent Sexual Transmission of HIV (Treatment as Prevention)
-
What to Start
-
Intro and Overview
- Table 6. Recommended Antiretroviral Regimens for Initial Therapy
-
Selecting an ART Regimen
- Table 7. Antiretroviral Regimen Considerations for Initial Therapy Based on Specific Clinical Scenarios
-
Nucleoside Reverse Transcriptase Inhibitor Options as Part of Initial Therapy
- Table 8a. Characteristics of Nucleoside Reverse Transcriptase Inhibitor Options Recommended for Antiretroviral Therapy-Naive Patients
-
Integrase Strand Transfer Inhibitor–Based Regimens
- Table 8b. Characteristics of Integrase Strand Transfer Inhibitors That Are Recommended for Antiretroviral Therapy–Naive Patients
-
Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens
- Table 8c. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)That Are Recommended as Initial Therapy for People with HIV
-
Protease Inhibitor-Based Regimens
- Table 8d. Characteristics of Protease Inhibitor Options That Are Recommended as Initial Therapy for People with HIV
- Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal
- Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy
- Table 10. Antiretroviral Components or Regimens Not Recommended as Initial Therapy
-
Intro and Overview
- What Not to Use
-
Management of the Treatment-Experienced Patient
-
Virologic Failure
- Table 11. Antiretroviral Options for Patients with Virologic Failure
- Poor CD4 Cell Recovery and Persistent Inflammation Despite Viral Suppression
- Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
- Discontinuation or Interruption of Antiretroviral Therapy
-
Virologic Failure
-
Special Patient Populations
-
Early (Acute and Recent) HIV Infection
- Table 12. Identifying, Diagnosing, and Treating Acute and Recent HIV Infection
-
Adolescents and Young Adults with HIV
- Table 13. Antiretroviral Therapy-Specific Strategies to Improve Medication Adherence
- Table 14: Approaches to Optimize Care Transition for AYA with HIV
- Table 15: AYA with HIV ARV Adherence Barriers and Strategies to Support Adherence
- HIV-2 Infection
- HIV and the Older Person
-
Substance Use Disorders and HIV
- Table 16. Medications for Treatment of Substance Use Disorders
-
Transgender People with HIV
- Table 17. Potential Interactions Between the Drugs Used in Gender-Affirming Hormone Therapy and Antiretroviral Drugs
- Women with HIV
-
Early (Acute and Recent) HIV Infection
- Considerations for Antiretroviral Use in Patients with Coinfections
-
Limitations to Treatment Safety and Efficacy
-
Adherence to the Continuum of Care
- Table 19. Strategies to Improve Linkage to Care, Retention in Care, Adherence to Appointments, and Adherence to Antiretroviral Therapy
-
Adverse Effects of Antiretroviral Agents
- Table 20. Common and/or Severe Adverse Effects Associated with Antiretroviral Therapy
- Table 21. Antiretroviral Therapy-Associated Adverse Effects That Can Be Managed with Substitution of Alternative Antiretroviral Agents
-
Cost Considerations and Antiretroviral Therapy
- Table 22a. Insurance and Health Program Prescription Drug Pricing and Access
- Table 22b. Monthly Average Prices of Commonly Used Antiretroviral Drugs
-
Adherence to the Continuum of Care
-
Drug-Drug Interactions
-
Overview
- Table 23. Mechanisms of Antiretroviral-Associated Drug Interactions
- Table 24a. Drug Interactions Between Protease Inhibitors and Other Drugs
- Table 24b. Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Other Drugs
- Table 24c. Drug Interactions Between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents)
- Table 24d. Drug Interactions Between Integrase Strand Transfer Inhibitors and Other Drugs
- Table 24e. Drug Interactions between the CCR5 Antagonist Maraviroc and Other Drugs (Including Antiretroviral Agents)
- Table 24f. Drug Interactions between HIV-1 gp120-Directed Attachment Inhibitors and Other Drugs (Including Antiretroviral Agents)
- Table 24g. Drug Interactions Between the Capsid Inhibitor Lenacapavir and Other Drugs (Including Antiretroviral Drugs)
- Table 25a. Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors
- Table 25b. Interactions between Integrase Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors
-
Overview
- Appendix A: Key to Acronyms
-
Appendix B: Drug Characteristics Tables
- Appendix B, Table 1. Coformulated and Copackaged Antiretroviral Regimens
- Appendix B, Table 2. Nucleoside Reverse Transcriptase Inhibitor-Based, Fixed-Dose Combination Tablets for Use as Part of an Antiretroviral Regimen
- Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors
- Appendix B, Table 4. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors
- Appendix B, Table 5. Characteristics of Protease Inhibitors
- Appendix B, Table 6. Characteristics of Integrase Inhibitors
- Appendix B, Table 7. Characteristics of the Fusion Inhibitor
- Appendix B, Table 8. Characteristics of the CCR5 Antagonist
- Appendix B, Table 9. Characteristics of CD4 Post-Attachment Inhibitor
- Appendix B, Table 10. Characteristics of the gp120 Attachment Inhibitor
- Appendix B, Table 11. Characteristics of the Capsid Inhibitor
- Appendix B, Table 12. Antiretroviral Dosing Recommendations in Adults with Renal or Hepatic Insufficiency
-
Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
- What's New in the Guidelines
- Introduction
- Bacterial Enteric Infections
- Bartonellosis
- Candidiasis (Mucocutaneous)
- Chagas Disease
- Coccidioidomycosis
- Community-Acquired Pneumonia
- Cryptococcosis
- Cryptosporidiosis
- Cystoisosporiasis (Formerly Isosporiasis)
- Cytomegalovirus Disease
- Hepatitis B Virus Infection
- Hepatitis C Virus
- Herpes Simplex Virus
- Histoplasmosis
- Human Herpesvirus-8 Disease
- Human Papillomavirus Disease
-
Immunizations for Preventable Diseases in Adults and Adolescents with HIV
- Recommended Adult Immunization Schedule by Medical Condition and Other Indications
- Recommended Immunization Schedule for Adults and Adolescents with HIV
- Leishmaniasis
- Malaria
- Microsporidiosis
- Mpox
- Disseminated Mycobacterium avium Complex Disease
-
Mycobacterium tuberculosis Infection and Disease
- Dosing Recommendations for Anti-TB Drugs for Treatment of Active Drug Sensitive TB
- Progressive Multifocal Leukoencephalopathy/JC Virus Infection
- Pneumocystis Pneumonia
- Syphilis
- Talaromycosis (formerly Penicilliosis)
- Toxoplasma gondii Encephalitis
- Varicella-Zoster Virus Disease
-
Tables
- Table 1. Chemoprophylaxis to Prevent First Episode of Opportunistic Disease
- Table 2. Treatment of HIV-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)
- Table 3. Indications for Discontinuing and Restarting Opportunistic Infection Prophylaxis in HIV-Infected Adults and Adolescents
- Table 4. Significant Pharmacokinetic Interactions Between Drugs Used to Treat or Prevent Opportunistic Infections
- Table 5. Serious and/or Common Adverse Reactions Associated with Systemically Administered Drugs Used to Treat or Prevent Opportunistic Infections
- Table 6. Dosing Recommendations for Drugs Used to Treat or Prevent Opportunistic Infections That Require Dosage Adjustment in Patients with Renal Insufficiency
- Appendix A: List of Abbreviations
-
Appendix B: Panel Roster and Financial Disclosures
- Leadership
- Section Review Group
- Bacterial Enteric Infections
- Bartonellosis
- Candidiasis
- Community-Acquired Pneumonia
- Cryptosporidiosis/ Microsporidiosis
- Geographic Opportunistic Infections
- Hepatitis B Virus
- Hepatitis C Virus
- Herpes (HHV-8/CMV)
- Herpes (HSV/VZV)
- Human Papillomavirus
- Immunizations
- Invasive Mycoses
- Mpox
- Mycobacterium avium Complex
- Mycobacterium tuberculosis
- Pharmacology
- Progressive Multifocal Leukoencephalopathy
- Pneumocystis Pneumonia
- Pregnancy
- Syphilis
- Toxoplasma gondii
-
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
- What's New in the Guidelines
- Panel Members
- Financial Disclosure
-
Introduction
- Table 1. Outline of the Guidelines Development Process
- Table 2. Rating Scheme for Recommendations
- Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure
- Infant Feeding for Individuals with HIV in the United States
-
Diagnosis of HIV Infection in Infants and Children
- Table 3. Recommended Virologic Testing Schedules for Infants Who Were Exposed to HIV According to Risk of Perinatal HIV Acquisition at and After Birtha
-
Clinical and Laboratory Monitoring of Pediatric HIV Infection
- Table 4. Characteristics and Requirements for In-Person Clinic Visits vs. Telemedicine Visits
- Table 5. CD4 Cell Counts and Percentages in Healthy Children: Distribution by Age
- Table 6. Sample Schedule for Clinical and Laboratory Monitoring of Children Before and After Initiation of Antiretroviral Therapy
- Table 7. Primary Food and Drug Administration-Approved Assays for Monitoring Viral Load
-
What to Start
-
Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children
- Preferred Regimen by Age, Weight, and Drug Class
- Table 8. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children
- Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children
-
Regimens Not Recommended for Use in Antiretroviral-Naive Children
- Table 10. Antiretroviral Regimens or Components That Are Not Recommended for Initial Treatment of HIV Infection in Children and Adolescents
- Table 11. Antiretroviral Regimens or Components That Are Never Recommended for Treating HIV in Children and Adolescents
-
Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children
- When to Initiate Therapy in Antiretroviral-Naive Children
-
Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection
- Table 12. Neonatal Antiretroviral Management According to Risk of HIV Infection in the Newborn
- Table 13. Antiretroviral Drug Dosing Recommendations for Newborns
- Table 14. Infant Antiretroviral Prophylaxis for Newborns of Mothers With Sustained Viral Suppression Who Breastfeed
- Special Considerations for Antiretroviral Therapy Use in Adolescents with HIV
-
Adherence to Antiretroviral Therapy in Children and Adolescents with HIV
- Table 15. Approaches for Monitoring Medication Adherence
- Table 16. Strategies to Improve Adherence to Antiretroviral Medications
-
Management of Medication Toxicity or Intolerance
- Overview
- Central Nervous System Toxicity
- Dyslipidemia
- Gastrointestinal Effects
- Hematologic Effects
- Hepatic Events
- Insulin Resistance, Asymptomatic Hyperglycemia, Diabetes Mellitus
- Lactic Acidosis
- Lipodystrophies and Weight Gain
- Nephrotoxic Effects
- Osteopenia and Osteoporosis
- Rash and Hypersensitivity Reactions
-
Management of Children Receiving Antiretroviral Therapy
- Overview
-
Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy
- Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression
-
Recognizing and Managing Antiretroviral Treatment Failure
- Table 19. Discordance Among Virologic, Immunologic, and Clinical Responses
- Table 20. Options for Regimens with at Least Two Fully Active Agents to Achieve Virologic Suppression in Patients with Virologic Failure and Evidence of Viral Resistance
- Antiretroviral Treatment Interruption in Children with HIV
-
Appendix A: Pediatric Antiretroviral Drug Information
- Capsid Inhibitors
- Overview
- Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTIs)
- Non-Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)
- Protease Inhibitors (PIs)
- Entry and Fusion Inhibitors
- Integrase Inhibitors
- Pharmacokinetic Enhancers
- Fixed-Dose Combinations
- Archived Drugs
- Appendix B: Acronyms
- Appendix C: CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Diseases Categorization
- Appendix D: Supplemental Information
-
Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV
- COVID-19
- What's New in the Guidelines
-
Introduction
- Table 1: Sexual Maturity Rating
- Table 2: HIV infection stage* Based on Age-Specific CD4+ T-Lymphocyte (CD4) Cell Count or CD4 Percentage of Total Lymphocytes
- Table 3: Recommendations Rating Scheme
- Preventing Vaccine-Preventable Diseases in Children and Adolescents with HIV Infection
-
Bacterial Infections
- Dosing Recommendations for Prevention and Treatment of Invasive Bacterial Infections
-
Candida Infections
- Dosing Recommendations for Prevention and Treatment of Candidiasis
-
Coccidioidomycosis
- Dosing Recommendations for Prevention and Treatment of Coccidioidomycosis
-
Cryptococcosis
- Dosing Recommendations for Prevention and Treatment of Cryptococcosis
-
Cryptosporidiosis
- Dosing Recommendations for Prevention and Treatment of Cryptosporidiosis
-
Cytomegalovirus
- Dosing Recommendations for Preventing and Treating Cytomegalovirus
-
Giardiasis
- Dosing Recommendations for Prevention and Treatment of Giardiasis
-
Hepatitis B Virus
- Dosing Recommendations for Prevention and Treatment of HBV in HIV/HBV Coinfected Children
-
Hepatitis C Virus
- Dosing Recommendations for Prevention and Treatment of Hepatitis C Virus (HCV)
- Herpes Simplex Virus
-
Histoplasmosis
- Dosing Recommendations for Preventing and Treating Histoplasmosis
-
Human Papillomavirus
- Dosing Recommendations for Prevention and Treatment of Human Papillomavirus (HPV)
-
Isosporiasis (Cystoisosporiasis)
- Dosing Recommendations for Preventing and Treating Isosporiasis (Cystoisosporiasis)
- Malaria
-
Microsporidiosis
- Dosing Recommendations for Preventing and Treating Microsporidiosis
- Mpox
-
Mycobacterium avium Complex Disease
- Dosing Recommendations for Prevention and Treatment of Mycobacterium avium Complex (MAC)
-
Mycobacterium tuberculosis
- Dosing Recommendations for Preventing and Treating TB in Children with HIV
-
Pneumocystis jirovecii Pneumonia
- Dosing Recommendations for Prevention and Treatment of Pneumocystis Pneumonia
-
Syphilis
- Dosing Recommendations for Prevention and Treatment of Syphilis
-
Toxoplasmosis
- Dosing Recommendations for Prevention and Treatment of Toxoplasmosis
-
Varicella-Zoster Virus
- Dosing Recommendations for Preventing and Treating Varicella-Zoster Virus
- Appendices
- Figures
-
Tables
- Table 1. Primary Prophylaxis
- Table 2. Secondary Prophylaxis
- Table 3. Treatment
- Table 4. Common Drugs Used for Treatment of Opportunistic Infections in Children with HIV: Preparations and Major Toxicities
- Table 5. Significant Drug Interactions for Drugs Used to Treat or Prevent Opportunistic Infections
-
Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States
- What's New in the Guidelines
- Panel Roster
- Financial Disclosure
-
Introduction
- Table 1. Outline of the Guidelines Development Process
- Table 2. Rating Scheme for Recommendations
- Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure
- Pre-exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods
-
Pregnancy Counseling and Care for People of Childbearing Age With HIV
-
Overview
- Table 3. Drug Interactions Between Antiretroviral Agents and Hormonal Contraceptives
- Reproductive Options When One or Both Partners Have HIV
-
Overview
-
Antepartum Care for Individuals with HIV
-
Overview
- Table 4. Antepartum Screenings and Assessments for Pregnant People with HIV
- Initial Evaluation and Continued Monitoring of HIV During Pregnancy
- Antiretroviral Drug Resistance and Resistance Testing in Pregnancy
-
Overview
-
Recommendations for the Use of Antiretroviral Drugs During Pregnancy
- Overview
- Use of Antiretroviral Drugs to Prevent Perinatal HIV Transmission and Improve Health for Pregnant People
- Antiretroviral Therapy for People With HIV Who Are Trying to Conceive
- Pregnant People With HIV Who Have Never Received Antiretroviral Drugs (Antiretroviral-Naive)
- People With HIV Who Are Taking Antiretroviral Therapy When They Become Pregnant
- Pregnant People With HIV Who Have Previously Received Antiretroviral Medications but Are Not Currently on Antiretroviral Medications
- Pregnant People Who Have Not Achieved Viral Suppression on Antiretroviral Therapy
- Table 6. What to Start: Initial Antiretroviral Regimens During Pregnancy for People Who Are Antiretroviral-Naive
- Table 7. Situation-Specific Recommendations for Use of Antiretroviral Drugs in Pregnant People and Nonpregnant People Who Are Trying to Conceive
-
Teratogenicity
- Table 8. Drug-Specific Risk Assessment by the Antiretroviral Pregnancy Registry
- Antiretroviral Drug Regimens and Pregnancy Outcomes
-
Special Populations
- Hepatitis B Virus/HIV Coinfection
- Hepatitis C Virus/HIV Coinfection
- HIV-2 Infection and Pregnancy
- Prenatal Care, Antiretroviral Therapy, and HIV Management in People with Perinatally Acquired HIV Infection
- Perinatal HIV Prevention for Transgender and Gender-Diverse People Assigned Female at Birth
- Early (Acute and Recent) HIV Infection
-
Intrapartum Care for People With HIV
- Table 9. Intrapartum Care and Recommended Interventions to Prevent Perinatal HIV Transmission for Pregnant People with HIV Based on HIV RNA Levels at the Time of Delivery
- Postpartum Follow-Up of People with HIV
- Infant Feeding for Individuals with HIV in the United States
-
Management of Infants Born to People with HIV Infection
-
Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection
- Table 10. Neonatal Antiretroviral Management According to Risk of HIV Infection in the Newborn
- Table 11. Antiretroviral Drug Dosing Recommendations for Newborns
- Table 12. Infant Antiretroviral Prophylaxis for Newborns of Mothers With Sustained Viral Suppression Who Breastfeed
-
Diagnosis of HIV Infection in Infants and Children
- Table 13. Recommended Virologic Testing Schedules for Infants Who Were Exposed to HIV According to Risk of Perinatal HIV Acquisition at and After Birth
- Initial Postnatal Management of the Neonate Exposed to HIV
- Long-Term Follow-Up of Infants Exposed to Antiretroviral Drugs
-
Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection
- Appendix A: Key to Acronyms
-
Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
- Table 14. Antiretroviral Drug Use in Pregnant People With HIV: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy | Overview
- Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Entry and Attachment Inhibitors
- Capsid Inhibitors
- Integrase Inhibitors
- Pharmacoenhancers
- Archived Drugs
- Antiretroviral Pregnancy Registry
- Appendix C: Antiretroviral Counseling Guide for Health Care Providers
- Appendix D: Review of Clinical Trials of Antiretroviral Interventions to Prevent Perinatal HIV Transmission
- Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Who Have Been Displaced by Disasters (such as a Hurricane)
- Guidance for COVID-19 and People with HIV
- Archived Guidelines
Drug Database
- 10-1074 Patient Version
- 3BNC117 Patient Version
- Abacavir / Dolutegravir / Lamivudine
- Abacavir / Lamivudine
- Abacavir
- Acyclovir
- Albendazole
- Albuvirtide Patient Version
- Amoxicillin / Clavulanate Potassium
- Amoxicillin
- Amphotericin B
- Atazanavir / Cobicistat
- Atazanavir
- Atovaquone
- Azithromycin
- Benznidazole
- Bictegravir / Emtricitabine / Tenofovir Alafenamide
- Brincidofovir Patient Version
- Butoconazole Nitrate
- Cabotegravir / Rilpivirine
- Cabotegravir
- ChAdV63.HIVconsv Patient Version
- Cidofovir (Injection)
- Ciprofloxacin
- Clarithromycin
- Clindamycin
- Cobicistat
- Dapivirine Patient Version
- Dapsone (Oral)
- Darunavir / Cobicistat / Emtricitabine / Tenofovir Alafenamide
- Darunavir / Cobicistat
- Darunavir
- Dolutegravir / Lamivudine
- Dolutegravir / Rilpivirine
- Dolutegravir
- Doravirine
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
- Doxorubicin Hydrochloride (Liposomal)
- Doxycycline
- Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate
- Efavirenz / Lamivudine / Tenofovir Disoproxil Fumarate
- Efavirenz / Lamivudine / Tenofovir Disoproxil Fumarate
- Efavirenz
- Elbasvir / Grazoprevir
- Elsulfavirine Patient Version
- Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide
- Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate
- Emtricitabine / Rilpivirine / Tenofovir Alafenamide
- Emtricitabine / Rilpivirine / Tenofovir Disoproxil Fumarate
- Emtricitabine / Tenofovir Alafenamide
- Emtricitabine / Tenofovir Disoproxil Fumarate
- Emtricitabine
- Enfuvirtide
- Entecavir
- Erythromycin
- Ethambutol Hydrochloride
- Etravirine
- Famciclovir
- Fidaxomicin
- Fluconazole
- Flucytosine
- Fosamprenavir
- Foscarnet Sodium
- Fostemsavir
- Ganciclovir
- Gentamicin
- Glecaprevir / Pibrentasvir
- Hepatitis A and Hepatitis B (Recombinant) Vaccine
- Hepatitis B Vaccine
- Human Papillomavirus 9-Valent Vaccine, Recombinant
- Ibalizumab-uiyk
- Imiquimod
- Influenza Virus Vaccines, Inactivated or Recombinant
- Islatravir Patient Version
- Isoniazid
- Itraconazole
- Lamivudine / Tenofovir Disoproxil Fumarate
- Lamivudine / Zidovudine
- Lamivudine
- Ledipasvir/Sofosbuvir
- Lefitolimod Patient Version
- Lenacapavir (HIV prevention) Patient Version
- Lenacapavir
- Leronlimab Patient Version
- Levofloxacin
- Lopinavir / Ritonavir
- MVA.HIVconsv Patient Version
- Maraviroc
- Miconazole
- Moxifloxacin Hydrochloride
- Nevirapine
- Nifurtimox
- PGDM1400 Patient Version
- PGT121 Patient Version
- Panobinostat Patient Version
- Peginterferon Alfa-2a (HBV, HCV)
- Peginterferon Alfa-2a (HIV) Patient Version
- Peginterferon Alfa-2b (HIV) Patient Version
- Penicillin G (Potassium or Sodium)
- Penicillin G Benzathine
- Pentamidine Isethionate
- Pneumococcal Conjugate Vaccines (15-Valent and 20-Valent)
- Pneumococcal Vaccine, Polyvalent
- Podofilox
- Primaquine Phosphate
- Pyrazinamide
- Pyridostigmine Patient Version
- Pyrimethamine
- Raltegravir
- Ribavirin
- Rifabutin
- Rifampin
- Rifapentine
- Rilpivirine
- Ritonavir
- Rituximab
- Romidepsin Patient Version
- SB-728-T Patient Version
- Semzuvolimab Patient Version
- Sinecatechins
- Smallpox and Mpox Vaccine
- Sofosbuvir / Velpatasvir / Voxilaprevir
- Sofosbuvir
- Sofosbuvir/Velpatasvir
- Somatropin Patient Version
- Sulfadiazine
- Sulfamethoxazole / Trimethoprim
- Tecovirimat Patient Version
- Tenofovir Alafenamide
- Tenofovir Disoproxil Fumarate
- Tenofovir-Based Microbicides Patient Version
- Terconazole
- Tipranavir
- Tucidinostat Patient Version
- VH3810109 Patient Version
- VRC01 Patient Version
- VRC07-523LS Patient Version
- Vaccinia Immune Globulin (Human) Patient Version
- Valacyclovir Hydrochloride
- Valganciclovir Hydrochloride
- Vancomycin Hydrochloride
- Varicella Virus Vaccine Live
- Varicella Zoster Immune Globulin (Human)
- Vedolizumab Patient Version
- Vesatolimod Patient Version
- Vorinostat Patient Version
- Zidovudine
- Zoster Vaccine Recombinant, Adjuvanted
Glossary
- AIDS Case Definition
- AIDS Clinical Trials Group (ACTG)
- AIDS Dementia Complex (ADC)
- AIDS Drug Assistance Programs (ADAPs)
- AIDS Education and Training Centers (AETCs)
- AIDS Service Organization (ASO)
- AIDS-Defining Condition
- AIDS-Related Cancer
- Absolute Contraindication
- Acanthosis Nigricans
- Acquired Immunity
- Acquired Immunodeficiency Syndrome (AIDS)
- Acquired Resistance
- Active Immunity
- Acute HIV Infection
- Acute Retinal Necrosis (ARN)
- Adenopathy
- Adenovirus
- Adherence
- Adjuvant
- Adverse Event (AE)
- Agammaglobulinemia
- Agency for Healthcare Research and Quality (AHRQ)
- Alanine Aminotransferase (ALT)
- Albumin
- Alkaline Phosphatase (ALP)
- Alopecia
- Amino Acids
- Analytical Treatment Interruption (ATI)
- Anemia
- Antacid(s)
- Antepartum
- Antibiotic
- Antibody Differentiation Test
- Antibody
- Anticoagulant
- Antifungal
- Antigen
- Antigen-Presenting Cell (APC)
- Antigen/Antibody Combination Test
- Antineoplastic
- Antiprotozoal
- Antiretroviral (ARV)
- Antiretroviral Pregnancy Registry
- Antiretroviral Therapy (ART)
- Antiretroviral Toxic Neuropathy (ATN)
- Antisense Antiviral
- Antiviral
- Aphthous Ulcer
- Apoptosis
- Approved Drug
- Area Under the Curve (AUC)
- Arm
- Arrhythmia
- Arthralgia
- Aspartate Aminotransferase (AST)
- Aspergillosis
- Assembly
- Asthenia
- Ataxia
- Atherosclerosis
- Attachment Inhibitor
- Autoimmune Disorder
- Avascular Necrosis (AVN)
- B Lymphocyte
- B-Cell Lymphoma
- BID
- Backbone
- Bactericidal Drug
- Bacteriostatic Drug
- Bacterium
- Bartonellosis
- Baseline
- Basophil
- Beta-2 Microglobulin (B2M)
- Bilirubin
- Binding
- Bioavailability
- Biological Response Modifiers (BRMs)
- Biopsy
- Blip
- Blood-Brain Barrier
- Body Habitus Changes
- Bone Marrow
- Boosting
- Boxed Warning
- Broadly Neutralizing Antibodies (bNAbs)
- Bronchitis
- Bronchoscopy
- Bronchospasm
- Budding
- Burkitt Lymphoma
- CCR5 Antagonist
- CCR5
- CD4 Count
- CD4 Percentage
- CD4 Receptor
- CD4 T Lymphocyte
- CD8 T Lymphocyte
- CDC-INFO
- CXCR4 Antagonist
- CXCR4
- CYP3A4
- Cachexia
- Campylobacteriosis
- Candidiasis
- Capsid Inhibitor(s)
- Capsid
- Cardiomyopathy
- Cardiovascular
- Cell-Mediated Immunity
- Centers for Disease Control and Prevention (CDC)
- Centers for Disease Control and Prevention-National Prevention Information Network (CDC-NPIN)
- Centers for Medicare and Medicaid Services (CMS)
- Central Nervous System (CNS)
- Cerebrospinal Fluid (CSF)
- Cervical Cancer
- Cervix
- Cesarean Delivery
- Cesarean Section
- Chagas Disease
- Chancroid
- Chemokines
- Chemoprevention
- Chemotherapy
- Child-Turcotte-Pugh Classification System
- Chlamydia
- Cholangiopathy
- Cholesterol
- Chromosome
- Chronic HIV Infection
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Circumoral
- Cisgender
- Class-Sparing Regimen
- Clastogenic
- Clinical Alert
- Clinical Endpoint
- Clinical Hold
- Clinical Progression
- Clinical Trial
- ClinicalInfo
- ClinicalTrials.gov
- Clinicalinfo Español
- Cmax
- Cmin
- Coagulopathy
- Coccidioidomycosis
- Cognitive Impairment
- Cohort
- Coinfection
- Colitis
- Communicable Disease
- Community-Acquired Pneumonia (CAP)
- Community-Based Organization (CBO)
- Comorbidity
- Complementary and Alternative Medicine (CAM)
- Complete Blood Count (CBC)
- Comprehensive Metabolic Panel (CMP)
- Condom
- Conjunctivitis
- Contagious Disease
- Contraindication
- Control Arm
- Controlled Trial
- Coronary Heart Disease (CHD)
- Correceptor
- Cross Resistance
- Cross Sensitivity
- Cryotherapy
- Cryptococcal Meningitis
- Cryptococcosis
- Cryptosporidiosis
- Cryptosporidium
- Crystalluria
- Cutaneous
- Cystoisosporiasis
- Cytochrome P450 (CYP450)
- Cytokine
- Cytomegalovirus (CMV)
- Cytomegalovirus Retinitis
- Cytopenia
- Cytotoxic
- Data and Safety Monitoring Board (DSMB)
- Definitive
- Dendritic Cell Vaccine
- Dendritic Cell
- Deoxyribonucleic Acid (DNA)
- Depression
- Desensitization
- Desiccant
- Diabetes
- Directly Observed Therapy (DOT)
- Disseminated
- Distal Sensory Polyneuropathy (DSP)
- Division of Acquired Immunodeficiency Syndrome (DAIDS)
- Dorsocervical Fat Pad
- Dosage Form
- Dosage
- Dose
- Dose-Ranging Trial
- Dose-Response Relationship
- Double-Blind Study
- Drug Antagonism
- Drug Class
- Drug Concentration
- Drug Interaction
- Drug Resistance
- Drug Synergism
- Drug-Drug Interaction
- Drug-Food Interaction
- Drug-Susceptible HIV
- Dual Energy X-Ray Absorptiometry (DXA, DEXA)
- Dual-Tropic Virus
- Dual/Mixed Tropic Virus
- Dyslipidemia
- Dysplasia
- Dyspnea
- Ecchymosis
- Edema
- Efficacy
- Eligibility Criteria
- Elite Controllers
- Embryo
- Empiric Therapy
- Encephalitis
- End-Stage Liver Disease (ESLD)
- End-Stage Renal Disease (ESRD)
- Endemic
- Enteric
- Enteric-Coated (EC)
- Enteritis
- Entry Inhibitor
- Env
- Envelope
- Enzyme
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Eosinophilia
- Eosinophilic Folliculitis (EF)
- Epidemic
- Epidemiology
- Epithelium
- Epitope
- Epstein-Barr Virus (EBV)
- Eradication
- Erythema Multiforme
- Erythema
- Etiology
- Expanded Access
- Experimental Arm
- Extensively Drug-Resistant Tuberculosis (XDR-TB)
- False Negative
- False Positive
- Fanconi Syndrome
- Fetus
- First-Line Therapy
- Fixed-Dose Combination (FDC)
- Formulation
- Functional Monotherapy
- Fungus
- Fusion Inhibitor
- Fusion
- Gag
- Gamma Globulin
- Gamma-Glutamyl Transpeptidase (GGT)
- Gastroenteritis
- Gastrointestinal (GI)
- Gender-Affirming Hormone Therapy (GHT)
- Gene Therapy
- Gene
- Generic Drug
- Genetic Engineering
- Genital Ulcer Disease
- Genital Warts
- Genitourinary Tract
- Genome
- Genotypic Antiretroviral Resistance Test (GART)
- Glucose
- Glycoprotein
- Gonorrhea
- Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)
- Granulocyte
- Granulocyte-Colony Stimulating Factor (G-CSF)
- Granulocytopenia
- Guillain-Barré Syndrome (GBS)
- Gynecomastia
- HELLP Syndrome
- HIV Continuum of Care
- HIV Navigation
- HIV Prevention Trials Network (HPTN)
- HIV Progression
- HIV Vaccine Trials Network (HVTN)
- HIV-1
- HIV-2
- HIV-Associated Nephropathy (HIVAN)
- HIV-Associated Neurocognitive Disorders (HAND)
- HLA-B*5701 Test
- Half-Life (t½)
- Health Resources and Services Administration (HRSA)
- Hematocrit
- Hematotoxic
- Hematuria
- Hemoglobin
- Hemolysis
- Hemophilia
- Hemorrhage
- Hepatic Necrosis
- Hepatic Steatosis
- Hepatic
- Hepatitis A Virus Infection (HAV)
- Hepatitis B Virus Infection (HBV)
- Hepatitis C Virus Infection (HCV)
- Hepatitis
- Hepatomegaly
- Hepatotoxicity
- Herpes Simplex Virus (HSV)
- Herpes Simplex Virus 1 (HSV-1) Infection
- Herpes Simplex Virus 2 (HSV-2) Infection
- Herpesviruses
- Histoplasmosis
- Hodgkin Lymphoma
- Hormone
- Host
- Human Growth Hormone (hGH)
- Human Immunodeficiency Virus (HIV)
- Human Leukocyte Antigen Complex
- Human Papillomavirus (HPV)
- Human T-Cell Lymphotropic Virus Type I (HTLV-I)
- Humoral Immunity
- Hypergammaglobulinemia
- Hyperglycemia
- Hyperlipidemia
- Hyperplasia
- Hypersensitivity Syndrome
- Hypersensitivity
- Hypertension
- Hypertriglyceridemia
- Hyperuricemia
- Hypogammaglobulinemia
- Hypogonadism
- Hypoxia
- Idiopathic
- Immune Complex
- Immune Modulators
- Immune Reconstitution Inflammatory Syndrome (IRIS)
- Immune Response
- Immune System
- Immune Thrombocytopenia (ITP)
- Immunity
- Immunocompetent
- Immunocompromised
- Immunodeficiency
- Immunogenicity
- Immunologic
- Immunosuppression
- Immunotherapy
- Implant
- In Vitro Fertilization (IVF)
- In Vitro
- In Vivo
- In utero
- Incidence
- Incubation Period
- Indian Health Service (IHS)
- Indication
- Infection
- Infectious Disease
- Infectious
- Informed Consent
- Infusion
- Injection Drug Use
- Injection Site Reaction
- Innate Immunity
- Institutional Review Board (IRB)
- Insulin Resistance
- Insulin Sensitivity
- Insulin
- Integrase Strand Transfer Inhibitor (INSTI)
- Integrase
- Integration
- Interferon (IFN)
- Interleukin-2 (IL-2)
- Interleukin-7 (IL-7)
- International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group
- International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
- Interstitial Nephritis
- Intervention
- Interventional Trial
- Intracytoplasmic Sperm Injection (ICSI)
- Intradermal
- Intramuscular (IM)
- Intrapartum
- Intrauterine Insemination (IUI)
- Intravaginal Ring (IVR)
- Intravaginal
- Intravenous (IV)
- Intravenous Immunoglobulin (IVIG)
- Invasive
- Investigational Drug
- Investigational New Drug Application (IND)
- Ischemia
- Jaundice
- Kaposi Sarcoma (KS)
- Kaposi Sarcoma-Associated Herpesvirus (KSHV)
- Karnofsky Performance Status (KPS)
- Kernicterus
- Kidneys
- LGBTQI+
- Lactic Acid
- Lactic Acidosis
- Latencia clínica
- Latency-Reversing Agents
- Latent HIV Reservoir
- Latent Tuberculosis Infection (LTBI)
- Leishmaniasis
- Lentivirus
- Lesion
- Leukocytosis
- Leukopenia
- Life Cycle
- Linear Gingival Erythema (LGE)
- Lipid Profile
- Lipid
- Lipoatrophy
- Lipodystrophy Syndrome
- Lipohypertrophy
- Lipoma
- Live Attenuated
- Liver Function Test
- Liver
- Localized
- Log10
- Long-Term Nonprogressors (LTNP)
- Lymph Nodes
- Lymph
- Lymphadenopathy
- Lymphatic System
- Lymphocyte Proliferation Assay
- Lymphocyte
- Lymphogranuloma Venereum (LGV)
- Lymphoid Interstitial Pneumonitis (LIP)
- Lymphoma
- Lymphopenia
- Lymphoproliferative Response
- Lysis
- MEDLINE
- MSM
- MSMW
- Macrophage
- Magnetic Resonance Imaging (MRI)
- Maintenance Therapy
- Malabsorption Syndrome
- Malaise
- Malaria
- Male Circumcision
- Malignant
- Mast Cell
- Maturation Inhibitor(s)
- Medication Event Monitoring System (MEMS)
- MedlinePlus
- Memory Lymphocyte
- Meningitis
- Messenger RNA (mRNA)
- Metabolic Syndrome
- Metabolic
- Metabolism
- Microbicide Trials Network (MTN)
- Microbicide
- Microorganism
- Microsporidiosis
- Mitochondrial Toxicity
- Mitocondria
- Mixed-Tropic HIV
- Modified Directly Observed Therapy (m-DOT)
- Molluscum Contagiosum
- Monoinfection
- Mononeuropathy
- Monotherapy
- Morbidity
- Mortality
- Mpox Virus
- Mpox
- Mucocutaneous
- Multicenter AIDS Cohort Study (MACS)
- Multicentric Castleman Disease (MCD)
- Multidrug-Resistant HIV (MDR-HIV)
- Multidrug-Resistant Tuberculosis (MDR-TB)
- Multipurpose Prevention Technology (MPT)
- Mutagenic
- Mutation
- Myalgia
- Mycobacterium Avium Complex (MAC) Infection
- Mycobacterium Kansasii Infection
- Mycobacterium Tuberculosis
- Mycosis
- Myelin
- Myelosuppression
- Myocardial Infarction
- Myopathy
- NNRTI-Sparing Regimen
- NRTI-Sparing Regimen
- Nadir
- National Cancer Institute (NCI)
- National Center for Complementary and Integrative Health (NCCIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health (NIH)
- National Library of Medicine (NLM)
- Natural History Study
- Natural Killer (NK) Cell
- Navigator
- Nemaline Rod Myopathy (NM)
- Neonatal
- Neoplasm
- Nephritis
- Nephrolithiasis
- Nephrotoxic
- Neuralgia
- NeuroAIDS
- Neuropathy
- Neutropenia
- Neutrophil
- New Drug Application (NDA)
- Non-Hodgkin Lymphoma (NHL)
- Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- Noninferiority Trial
- Nonoccupational Postexposure Prophylaxis (nPEP)
- Nonreactive Test Result
- Nonsteroidal Anti-Inflammatory Drug (NSAID)
- Nucleic Acid Test (NAT)
- Nucleic Acid
- Nucleoside Reverse Transcriptase Inhibitor (NRTI)
- Nucleoside
- Nucleotide Reverse Transcriptase Inhibitor (NtRTI)
- Nucleotide
- Nucleus
- Observational Trial
- Occupational Exposure
- Occupational Postexposure Prophylaxis (oPEP)
- Off-Label Use
- Office of AIDS Research (OAR)
- Office of Minority Health (OMH)
- On-Label Use
- Open-Label Trial
- Opportunistic Infection (OI)
- Optimized Background Therapy (OBT)
- Oral Hairy Leukoplakia (OHL)
- Osteonecrosis
- Osteopenia
- Osteoporosis
- PI-Sparing Regimen
- Package Insert
- Palliative Care
- Pancreas
- Pancreatitis
- Pancytopenia
- Pandemic
- Pap Smear
- Papilloma
- Parasite
- Parenteral
- Paresthesia
- Passive Immunity
- Passive Immunotherapy
- Pathogen
- Pathogenesis
- Pediatric AIDS Clinical Trials Group (PACTG)
- Pediatric AIDS Clinical Trials Group 076 (PACTG 076)
- Pelvic Inflammatory Disease (PID)
- People with HIV
- Peptide
- Perianal
- Perinatal Transmission
- Perinatal
- Peripheral Blood Mononuclear Cell (PBMC)
- Peripheral Nervous System (PNS)
- Peripheral Neuropathy
- Persistent Generalized Lymphadenopathy (PGL)
- Pharmacokinetic Enhancers
- Pharmacokinetics
- Pharmacology
- Phase 1 Trial
- Phase 2 Trial
- Phase 3 Trial
- Phase 4 Trial
- Phenotypic Antiretroviral Resistance Test
- Phenylketonuria
- Photosensitivity
- Pill Burden
- Placebo Effect
- Placebo
- Placebo-Controlled Trial
- Placenta
- Plasma
- Platelet
- Pneumocystis Jirovecii Pneumonia
- Pneumonia
- Pol
- Polineuritis
- Polymerase Chain Reaction (PCR)
- Polyneuropathy
- Polyvalent Vaccine
- Posnatal
- Postattachment Inhibitor
- Postexposure Prophylaxis (PEP)
- Postpartum
- PrEP Navigation
- Pre-Exposure Prophylaxis (PrEP)
- Preclinical
- Preconception Counseling and Care
- Prenatal
- President's Emergency Plan for AIDS Relief (PEPFAR)
- Presumptive
- Prevalence
- Prevention of Perinatal Transmission
- Preventive HIV Vaccine
- Primary Effusion Lymphoma (PEL)
- Primary Prophylaxis
- Primary Varicella Infection
- Proctitis
- Prodrome
- Progressive Multifocal Leukoencephalopathy (PML)
- Progressive Outer Retinal Necrosis (PORN)
- Prophylaxis
- Protease Inhibitor (PI)
- Protease
- Protein
- Proteinuria
- Protocol
- Protozoan
- Provirus
- Pruritus
- PubMed
- Pulmonary
- QD
- QID
- Qualitative Transcription-Mediated Amplification Assay
- Quantitative Branched DNA Assay (bDNA )
- Quasispecies
- R5-Tropic Virus
- Randomized Trial
- Rapid Test
- Reactive Test Result
- Receptor
- Rechallenge
- Recombinant
- Red Blood Cell
- Refractory
- Regimen Simplification
- Regulatory T Lymphocyte
- Relapse
- Relative Contraindication
- Remission
- Renal
- Replicate
- Replication
- Resistance Testing
- Retina
- Retinal Detachment
- Retinitis
- Retrospective Study
- Retrovirus
- Rev Inhibitor
- Reverse Transcriptase (RT)
- Reverse Transcriptase-Polymerase Chain Reaction-Based Assay (RT-PCR)
- Reverse Transcription
- Rhabdomyolysis
- Ribonucleic Acid (RNA)
- Rigors
- Ryan White HIV/AIDS Program
- Salmonella Septicemia
- Salmonella
- Salvage Therapy
- Seborrheic Dermatitis
- Secondary Transmission
- Self-Administered Therapy (SAT)
- Semen
- Sensitivity
- Sepsis
- Seroconcordant Couple
- Seroconversion
- Serodifferent Couple
- Serologic Test
- Seroprevalence
- Serostatus
- Serum
- Set Point
- Sexual Maturity Rating (SMR)
- Sexual Transmission
- Sexually Transmitted Infection (STI)
- Shigellosis
- Shingles
- Shock and Kill Strategy
- Simian Immunodeficiency Virus (SIV)
- Single-Blind Study
- Specificity
- Sperm Washing
- Spermicide
- Spinal Tap
- Spleen
- Splenomegaly
- Sputum Analysis
- Standard of Care
- Statin
- Stem Cells
- Stevens-Johnson Syndrome (SJS)
- Stigma
- Stomatitis
- Strain
- Streptococcus Pneumoniae Infection
- Stroke
- Structured Treatment Interruption
- Subclinical Infection
- Subcutaneous (SC, Sub-Q)
- Subcutaneous Adipose Tissue (SAT)
- Suboptimal Immunologic Response
- Substance Abuse and Mental Health Services Administration (SAMHSA)
- Subtype
- Sulfa Medicine(s)
- Superinfection
- Superiority Trial
- Surrogate Endpoint
- Syncytium
- Syndrome
- Syphilis
- Systemic
- T Lymphocyte
- T-Cell Exhaustion
- TID
- Tachycardia
- Tachypnea
- Talaromyces Marneffei Infection
- Teratogenic
- Testosterone
- Therapeutic Drug Monitoring (TDM)
- Therapeutic HIV Vaccine
- Therapeutic Index (TI)
- Thrombocytopenia
- Thymus
- Titer
- Tolerance
- Topical
- Toxic Epidermal Necrolysis (TEN)
- Toxicity
- Toxoplasma gondii Encephalitis
- Toxoplasmosis
- Transgender
- Transmission
- Transmitted Resistance
- Transplacental
- Treatment Failure
- Treatment Regimen
- Treatment as Prevention (TasP)
- Treatment-Experienced
- Treatment-Naive
- Triglycerides
- Triple-Class Experienced
- True Negative
- True Positive
- Tuberculin Skin Test
- Tuberculosis (TB)
- Tuberculosis Disease
- U.S. Department of Health and Human Services (HHS)
- U.S. Food and Drug Administration (FDA)
- Undetectable Viral Load
- Urinalysis (UA)
- Urolithiasis
- Urticaria
- Vaccination
- Vaccine
- Vacuolar Myelopathy
- Varicella Zoster Virus (VZV)
- Vector
- Viral Evolution
- Viral Latency
- Viral Load (VL)
- Viral Load Test
- Viral Rebound
- Viral Suppression
- Viral Tropism
- Viremia
- Viricide
- Virologic Failure
- Virology
- Virus
- Visceral Adipose Tissue (VAT)
- Vulvovaginal Candidiasis
- Wasting Syndrome
- Western Blot
- White Blood Cell
- Wild-Type Virus
- Window Period
- Women's Interagency HIV Study (WIHS)
- World Health Organization (WHO)
- X4-Tropic Virus
- gp120
- gp160
- gp41
- p24